BCRX
NASDAQ · Biotechnology
Biocryst Pharmaceuticals Inc
$9.70
-0.11 (-1.12%)
Open$9.73
Previous Close$9.81
Day High$10.32
Day Low$9.64
52W High$11.31
52W Low$6.00
Volume—
Avg Volume3.93M
Market Cap1.86B
P/E Ratio—
EPS$-0.05
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+581.6% upside
Current
$9.70
$9.70
Target
$66.12
$66.12
$46.17
$66.12 avg
$78.89
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 544.51M | 383.30M | 328.14M |
| Net Income | -107,374,547 | -68,025,547 | -56,674,354 |
| Profit Margin | -19.7% | -18.7% | -17.3% |
| EBITDA | -1,573,161 | -1,052,022 | -75,730,538 |
| Free Cash Flow | — | — | -52,199,092 |
| Rev Growth | +42.1% | +42.1% | +7.1% |
| Debt/Equity | 2.09 | 2.09 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |